“It’s designed to be simple in a way, even though it’s an incredibly complex device”, Distalmotion CEO Greg Roche explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Roche sits down with BI analyst Matt Henriksson for an in-depth interview on the company, how its Dexter Robotic Surgery System and single-use instrument platform differentiates itself from others in the robotic market and how it can shorten the learning curve that can increase adoption of robots in ambulatory surgical centers.

&ldquo;It&rsquo;s designed to be simple in a way, even though it&rsquo;s an incredibly complex device&rdquo;, Distalmotion CEO Greg Roche explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Roche sits down with BI analyst Matt Henriksson for an in-depth interview on the company, how its Dexter Robotic Surgery System and single-use instrument platform differentiates itself from others in the robotic market and how it can shorten the learning curve that can increase adoption of robots in ambulatory surgical centers.

Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Healthcare by Bloomberg Intelligence

Distalmotion’s Approach to Spread Surgical Robots to More

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/005146c4-089f-4e4e-983a-b46d010d541a/transcript

“Your doctor has more outdated technology than your Uber driver does,” Abhinav Shashank, co-founder and CEO of Innovaccer, tells Bloomberg Intelligence analyst Jonathan Palmer in this episode of the Vanguards of Healthcare podcast. Shashank explains why fixing healthcare’s fragmented data infrastructure is the foundation for the industry’s AI future and why long-term value will accrue to companies that own the data layer rather than the user interface. He also traces Innovaccer’s evolution from a data startup into a platform spanning 80 million patient lives, and argues that “autonomous healthcare” could strip hundreds of billions of dollars of administrative waste. The conversation explores the economics of AI, the danger of poorly designed automation, how acquisitions are filling gaps and Innovaccer’s ambition to reach $1 billion of annual recurring revenue.

&ldquo;Your doctor has more outdated technology than your Uber driver does,&rdquo; Abhinav Shashank, co-founder and CEO of Innovaccer, tells Bloomberg Intelligence analyst Jonathan Palmer in this episode of the Vanguards of Healthcare podcast. Shashank explains why fixing healthcare&rsquo;s fragmented data infrastructure is the foundation for the industry&rsquo;s AI future and why long-term value will accrue to companies that own the data layer rather than the user interface. He also traces Innovaccer&rsquo;s evolution from a data startup into a platform spanning 80 million patient lives, and argues that &ldquo;autonomous healthcare&rdquo; could strip hundreds of billions of dollars of administrative waste. The conversation explores the economics of AI, the danger of poorly designed automation, how acquisitions are filling gaps and Innovaccer&rsquo;s ambition to reach $1 billion of annual recurring revenue.

Innovaccer’s Bet on the Data Layer Powering Autonomous Healthcare

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/77114cc9-066e-40ca-8d1a-b4a500c71101/transcript

“We started using AI to enhance algorithms and software to better be able to understand the data that’s in each patient’s ECG. And our goal with that was to bring forward personalized medicine in arrhythmia therapy and improve patient outcomes,” Vektor Medical CEO Rob Krummen says while discussing vMap. In this episode of the Vanguards of Healthcare podcast, Krummen sits down with Bloomberg Intelligence analyst Matt Henriksson to discuss the expansion of the vMap system, which uses standard 12-lead electrocardiogram (ECG) readings to help physicians treat arrhythmia cases, including atrial fibrillation. He also covers the company’s strategy to democratize electrophysiology and get patients to ablation treatment as early as possible.

&ldquo;We started using AI to enhance algorithms and software to better be able to understand the data that&rsquo;s in each patient&rsquo;s ECG. And our goal with that was to bring forward personalized medicine in arrhythmia therapy and improve patient outcomes,&rdquo; Vektor Medical CEO Rob Krummen says while discussing vMap. In this episode of the Vanguards of Healthcare podcast, Krummen sits down with Bloomberg Intelligence analyst Matt Henriksson to discuss the expansion of the vMap system, which uses standard 12-lead electrocardiogram (ECG) readings to help physicians treat arrhythmia cases, including atrial fibrillation. He also covers the company&rsquo;s strategy to democratize electrophysiology and get patients to ablation treatment as early as possible.

Vektor Medical Applies AI to ECGs to Expand Arrhythmia Treatment Pathway

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/cbce9a45-331a-4fcd-a6f0-b49e00b62d7c/transcript

“Our focus is really on patients who’ve lost a lot of kidney function, 70 to 75% or even 80% of their kidney function,” says Bruce Culleton, CEO of ProKidney. “They’re on the path to needing a transplant. Despite all the advances in treating patients with newer products over the last few years, patients continue to progress. Our goal is to intervene directly before dialysis and keep patients off dialysis for as long as possible.” In this Vanguards of Healthcare podcast episode, Culleton sits down with Bloomberg Intelligence senior analyst Ann-Hunter van Kirk for an in-depth discussion about how the company’s cell therapy could help delay dialysis and slow the progression of kidney disease.

&ldquo;Our focus is really on patients who&rsquo;ve lost a lot of kidney function, 70 to 75% or even 80% of their kidney function,&rdquo; says Bruce Culleton, CEO of ProKidney. &ldquo;They&rsquo;re on the path to needing a transplant. Despite all the advances in treating patients with newer products over the last few years, patients continue to progress. Our goal is to intervene directly before dialysis and keep patients off dialysis for as long as possible.&rdquo; In this Vanguards of Healthcare podcast episode, Culleton sits down with Bloomberg Intelligence senior analyst Ann-Hunter van Kirk for an in-depth discussion about how the company&rsquo;s cell therapy could help delay dialysis and slow the progression of kidney disease.

ProKidney Aims to Stave Off Dialysis

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/b7bce1e6-c029-45a4-8b93-b49700cffd38/transcript

Distalmotion’s Approach to Spread Surgical Robots to More

In 1 playlist(s)

Vanguards of Healthcare by Bloomberg Intelligence

Social links

Follow podcast

Recent clips